These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Response to "A graphic reanalysis of the NINDS Trial". Dewey HM; Churilov L; Blacker D; Bladin C; Davis SM; Donnan GA; Gates P; Gerraty RP; Hand P; Levi C; Lindley RI; Markus R; Read S Ann Emerg Med; 2010 Feb; 55(2):227-9; author reply 229. PubMed ID: 20116035 [No Abstract] [Full Text] [Related]
5. Stroking the data: re-analysis of the NINDS trial. Magid D; Naviaux N; Wears RL Ann Emerg Med; 2005 Apr; 45(4):385-7. PubMed ID: 15795716 [No Abstract] [Full Text] [Related]
6. Thrombolysis for acute stroke: the incontrovertible, the controvertible, and the uncertain. Silbergleit R; Scott PA Acad Emerg Med; 2005 Apr; 12(4):348-51. PubMed ID: 15805327 [No Abstract] [Full Text] [Related]
7. Tissue plasminogen activator-induced reperfusion injury after stroke revisited. Hermann DM; Matter CM Circulation; 2007 Jul; 116(4):363-5. PubMed ID: 17646593 [No Abstract] [Full Text] [Related]
8. Thrombolysis in stroke: still not ready for community hospital use by emergency physicians. McNamara RM Ann Emerg Med; 2009 Sep; 54(3):339-41. PubMed ID: 19695417 [No Abstract] [Full Text] [Related]
9. [Thrombolytic therapy in acute ischemic stroke: present and future]. Mori E No Shinkei Geka; 2003 Mar; 31(3):249-60. PubMed ID: 12684978 [No Abstract] [Full Text] [Related]
10. A hundred (and one) graphs tell only part of the story. Silbergleit R Ann Emerg Med; 2009 Sep; 54(3):342-3. PubMed ID: 19695418 [No Abstract] [Full Text] [Related]
11. Emergency physician survey: recombinant tissue plasminogen activator for stroke. Mann J Ann Emerg Med; 2006 Oct; 48(4):476; author reply 477. PubMed ID: 16997689 [No Abstract] [Full Text] [Related]
12. Tissue plasminogen activator approved for stroke. Barber A; Gommans J N Z Med J; 2005 May; 118(1214):U1432. PubMed ID: 15886728 [No Abstract] [Full Text] [Related]
14. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T; Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715 [TBL] [Abstract][Full Text] [Related]
15. Is rt-PA useful for stroke after 3 hours? Nau JP JAAPA; 2004 Feb; 17(2):51-3. PubMed ID: 15307330 [No Abstract] [Full Text] [Related]
16. Using tPA for acute stroke in a rural setting. Edwards LL Neurology; 2007 Jan; 68(4):292-4. PubMed ID: 17242335 [TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134 [TBL] [Abstract][Full Text] [Related]
18. Thrombolytic therapy with alteplase for ischaemic stroke. Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701 [TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus. Fatovich DM Med J Aust; 2005 Jan; 182(1):44-5; author reply 45. PubMed ID: 15651951 [No Abstract] [Full Text] [Related]
20. Future of neuroprotective drugs in doubt. Birmingham K Nat Med; 2002 Jan; 8(1):5. PubMed ID: 11786882 [No Abstract] [Full Text] [Related] [Next] [New Search]